The InduBC Platforms of the Society is closing $15 million Series C Financing and Signs Agreement with IQVIA to Expand Data Analytics in the Genomicsstry Sub-Committee picked caplacizumab from a shortlist of outstanding first-class medicines and excellent presentations.

The InduBC Platforms of the Society is closing $15 million Series C Financing and Signs Agreement with IQVIA to Expand Data Analytics in the Genomicsstry Sub-Committee picked caplacizumab from a shortlist of outstanding first-class medicines and excellent presentations.

ZURICH, Switzerland and BOSTON, US, December 18, 2019/B3Cnewswire/–BC Platforms, a world leader in genomic data management and analytics, today announced the completion of a $15 million round of investment alongside a new strategic partnership with IQVIATM.

The round was funded by IQVIA in partnership with the Finnish venture capital and private equity firm Debiopharm Venture Fund and Tesi.

As part of the partnership, IQVIA and BC Platforms plan to launch new data-driven solutions to support development science, combining nuanced clinical and genomic data.

IQVIA and BC Platforms share the goal of developing a world-leading analytics platform to allow the pharmaceutical industry to advance precision medicine, increase drug development quality and improve patient outcomes.

BC Platforms platform will improve IQVIA’s E360TM Genomics— a flexible, privacy-conserving genotypic-phenotypic software system — to enable a federated genomic-related analytics data network designed to protect patient privacy.

BC Platforms will use the funding proceeds to extend the worldwide clinical and genomics data network, supplying pharmaceutical companies with innovative digital solutions. BC Platforms is one of the world’s leading suppliers of efficient tools for genomic data management and analysis.

The high-performance architecture for genomic data management facilitates scalable data aggregation, efficient research and molecular and clinical knowledge interpretation. To order to provide genetic and therapeutic cohort evidence for medicinal and medical research and development, the organization has launched and opened a global network of biobanks known as BCRQUEST.COM.

The goal of BC Platforms is to build the world’s largest health care and business insights platform by 2020, offering access to a variety of genetic and clinical data and samples from more than 5 million combined subjects a national network of biobanks combined.

Established in 1997 as a part of a spinoff MIT Whitehead initiative, the organization has a strong scientific tradition underpinned by more than 20 years of working closely with a network of leading researchers, engineers, suppliers and vendors.

With its offices in Zurich, Switzerland, BC Platforms has global operations, research and development in Espoo, Finland, and sales and marketing in Toronto, Houston, Vancouver and Singapore.

, ,